Literature DB >> 23633541

T315I, more or less, predicts for major molecular response: the devil is in the details!

Michael J Mauro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23633541      PMCID： PMC3640107          DOI： 10.3324/haematol.2013.084251

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Authors:  Jorge Cortes; Jeff H Lipton; Delphine Rea; Raghunadharao Digumarti; Charles Chuah; Nisha Nanda; Annie-Claude Benichou; Adam R Craig; Mauricette Michallet; Franck E Nicolini; Hagop Kantarjian
Journal:  Blood       Date:  2012-08-15       Impact factor: 22.113

2.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

3.  Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Authors:  Jirí Pavlu; Richard M Szydlo; John M Goldman; Jane F Apperley
Journal:  Blood       Date:  2010-10-21       Impact factor: 22.113

4.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

5.  BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Authors:  Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

6.  Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Authors:  Franck E Nicolini; Michael J Mauro; Giovanni Martinelli; Dong-Wook Kim; Simona Soverini; Martin C Müller; Andreas Hochhaus; Jorge Cortes; Charles Chuah; Inge H Dufva; Jane F Apperley; Fumiharu Yagasaki; Jay D Pearson; Senaka Peter; Cesar Sanz Rodriguez; Claude Preudhomme; Francis Giles; John M Goldman; Wei Zhou
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

7.  Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Authors:  Thomas Ernst; Philipp Erben; Martin C Müller; Peter Paschka; Thomas Schenk; Jana Hoffmann; Sebastian Kreil; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

8.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

9.  Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Authors:  Susan Branford; Junia V Melo; Timothy P Hughes
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

10.  The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Authors:  Thoralf Lange; Thomas Ernst; Franz X Gruber; Jacqueline Maier; Michael Cross; Martin C Müller; Dietger Niederwieser; Andreas Hochhaus; Markus Pfirrmann
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.